Prognostic role of hyponatremia in 564 small cell lung cancer patients treated with topotecan

Hyponatremia is an independent prognostic factor for patients with SCLC treated with topotecan in second-line setting. Further studies are needed to prospectically confirm these results and to develop an optimal therapy for hyponatremic patients.